The histone deacetylase (HDAC) inhibitor valproic acid as monotherapy or in combination with all‐trans retinoic acid in patients with acute myeloid leukemia

@article{Kuendgen2006TheHD,
  title={The histone deacetylase (HDAC) inhibitor valproic acid as monotherapy or in combination with all‐trans retinoic acid in patients with acute myeloid leukemia},
  author={A. Kuendgen and Mathias Schmid and R. P. Schlenk and S. Knipp and B. Hildebrandt and C. Steidl and U. Germing and R. Haas and H. Dōhner and N. Gattermann},
  journal={Cancer},
  year={2006},
  volume={106}
}
  • A. Kuendgen, Mathias Schmid, +7 authors N. Gattermann
  • Published 2006
  • Medicine
  • Cancer
  • Valproic acid (VPA) inhibits histone deacetylase activity and, synergizing with all‐trans retinoic acid (ATRA), achieves differentiation induction of myeloid blast cells in vitro. 
    218 Citations
    Valproic acid for the treatment of myeloid malignancies
    • 52
    Phase I trial of ATRA-IV and depakote in patients with advanced solid tumor malignancies
    • 21

    References

    SHOWING 1-10 OF 59 REFERENCES
    Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells
    • 1,615
    • PDF
    Histone Deacetylase Is a Target of Valproic Acid-Mediated Cellular Differentiation
    • 386
    • PDF
    Treatment of myelodysplastic syndromes with valproic acid alone or in combination with all-trans retinoic acid.
    • 246
    • PDF
    Histone deacetylases as therapeutic targets in hematologic malignancies.
    • 120
    Histone deacetylase inhibitors in cancer treatment.
    • 177
    The histone deacetylase inhibitor valproic acid selectively induces proteasomal degradation of HDAC2
    • 461
    Histone Deacetylase Is a Direct Target of Valproic Acid, a Potent Anticonvulsant, Mood Stabilizer, and Teratogen*
    • 1,525
    • PDF
    Inhibitors of histone deacetylase relieve ETO-mediated repression and induce differentiation of AML1-ETO leukemia cells.
    • 212
    • Highly Influential
    • PDF